Elaine Smith raises a very valid point. As she knows, the Medicines and Healthcare Products Regulatory Agency is the responsible body for the safety, equality and efficacy of all United Kingdom-licensed medicines. On 21 May, it issued advice to healthcare professionals regarding alternative arrangements for a continued supply of triiodothyronine, or T3. The issue is very much a reserved matter, particularly in relation to pricing, but I share Elaine Smith’s frustrations about the inflated prices. We are taking up the issue with the relevant authorities at United Kingdom level.